Zhi Tong Cai Jing·2025-08-28 12:36Core Viewpoint - Shanghai Pharmaceuticals (601607)(02607) reported a mid-year performance for 2025, showing a slight increase in revenue but a significant rise in net profit due to a change in accounting treatment for a subsidiary [1] Financial Performance - The company's operating revenue was approximately 141.59 billion yuan, representing a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders was about 4.46 billion yuan, reflecting a year-on-year increase of 51.56% [1] - Basic earnings per share stood at 1.2 yuan [1] Special Accounting Adjustments - The increase in net profit was primarily due to a one-time special gain resulting from the change in accounting treatment for Hutchison Whampoa from equity method accounting to subsidiary accounting [1] - Excluding this one-time special gain, the net profit attributable to shareholders was 2.78 billion yuan, which represents a year-on-year decline of 2.06% [1]